Rapport Therapeutics (RAPP) to Release Earnings on Monday

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.09. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rapport Therapeutics Stock Down 7.2%

NASDAQ:RAPP traded down $0.78 on Tuesday, hitting $10.04. The stock had a trading volume of 112,510 shares, compared to its average volume of 174,549. The company has a fifty day moving average price of $10.12 and a two-hundred day moving average price of $14.23. Rapport Therapeutics has a 1-year low of $6.43 and a 1-year high of $29.74. The stock has a market cap of $366.44 million and a price-to-earnings ratio of -2.91.

Analysts Set New Price Targets

RAPP has been the topic of several recent analyst reports. Citizens Jmp initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock. JMP Securities initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They issued a "market outperform" rating and a $28.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $32.67.

Insiders Place Their Bets

In other Rapport Therapeutics news, Director Wendy B. Young bought 6,000 shares of Rapport Therapeutics stock in a transaction on Wednesday, March 12th. The shares were bought at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Troy A. Ignelzi bought 9,900 shares of Rapport Therapeutics stock in a transaction on Wednesday, March 12th. The shares were acquired at an average price of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the acquisition, the chief financial officer now owns 9,900 shares in the company, valued at $99,990. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Rapport Therapeutics

A hedge fund recently bought a new stake in Rapport Therapeutics stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 203,242 shares of the company's stock, valued at approximately $2,039,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.56% of Rapport Therapeutics at the end of the most recent reporting period.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.